SEC Tracker
Get the app

Brooklyn ImmunoTherapeutics ERNA

Brooklyn ImmunoTherapeutics FY 2021: net loss $122.5M; diluted EPS −$56.60

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.26
Material contract

Key figures from this report

These are the numbers Brooklyn ImmunoTherapeutics reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$122.5MAgainst −$4.4M in FY 202010-K/A income statement, on EDGAR
  2. Diluted EPS−$56.60Against −$8.20 in FY 2020. Split-adjusted, as the tables show it; the filing reported −$2.8310-K/A income statement, on EDGAR
  3. Cash and cash equivalents$17.0M+2086% from $777K in FY 202010-K balance sheet, on EDGAR
  4. Cash from operations−$23.5MAgainst −$3.9M in FY 202010-K/A cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Brooklyn ImmunoTherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Marker Therapeutics MRKR public float $17M, Jun 30, 2025
  2. Charlie's Holdings CHUC public float $18M, Jun 30, 2025
  3. Cognition Therapeutics CGTX public float $18M, Jun 30, 2025
  4. IGC Pharma IGC public float $18M, Jun 30, 2025
  5. Lipocine LPCN public float $16M, Jun 30, 2025